Guest View
User: Pass: | become a member
Author Archive for Insider Scoop

Bob Peck Highlights Upbeat Sentiment On YouTube, Mobile On Google

Courtesy of Benzinga.

Bob Peck Highlights Upbeat Sentiment On YouTube, Mobile On Google
Related GOOG
Axiom: Google Quarter Boosted By TrueView Paid Clicks
Why Facebook's Quarter Might Be A 'Pretty Good Read Through' For Twitter
Yahoo Search May Offer Shareholders A Glimmer Of Hope (Seeking Alpha)
Related GOOGL
Why Facebook's Quarter Might Be A 'Pretty Good Read Through' For Twitter
US Stock Futures Up Ahead Of Durable-Goods Orders Data
Stock Futures Up, Techs Lead; Amazon, Starbucks, Google Climb (Investor’s Business Daily)

SunTrust commented on Google Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Friday and maintained a Buy rating with a $650 price target.

Google’s Q1 gross revenue came in at $17.3 billion, approximately 1 percent below the consensus of $17.5 billion. On an FX-neutral basis, revenue growth was fairly stable at approximately 17 percent, versus the reported growth of 12 percent, according to analyst Bob Peck.

Peck also discussed key “incremental takeaways” following Google’s Q1 earnings release.

First, Peck noted that lower CPC was “due to rapid growth of YouTube TrueView ads, which are brand-centric and thus monetize lower than search.”

"Google Sites CPC dynamic is not the result of challenges in monetizing mobile search, as many believe. In fact mobile search is showing 'real strength,'" according to Peck.

Peck felt it was a positive disclosure that, ex-TrueView, “Sites clicks growth would be lower, though still positive, and core search CPC would show increases.”

“YouTube, while not profitable yet, could be if reinvestment was pulled back,” Peck observed.

Second, Peck said that because “operating margin increased sequentially (by 2 points) for the first time in six quarters,” it supported the firm’s “thesis that the company could move to protect profitability and share price.”

The operating margin was 100 bps above consensus at 32.7 percent versus the expected 31.7 percent while FCF was also strong at $3.7 billion, a 4 percent FCF yield.

Related Link: Google Q1 Earnings Conference Call: A Play-By-Play Recap

continue reading

Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story

Courtesy of Benzinga.

Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story
Related GILD
Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni
Benzinga's M&A Chatter for Tuesday April 21, 2015
Merck's HCV combo shows cure rates of 60 – 100% in three genotypes (Seeking Alpha)
Related MRK
Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni
Morgan Stanley Awaits This Merck Data
Merck's HCV combo shows cure rates of 60 – 100% in three genotypes (Seeking Alpha)

In a report published Friday, Morgan Stanley analysts maintained an Overweight rating on Gilead Sciences, Inc. (NASDAQ: GILD). Headline SVR from Merck & Co., Inc. (NYSE: MRK) Naive Data does not “tell the whole story,” the analysts commented.

Although top-line Merck SVR12 was 95 percent, the company had significantly less of the harder-to-treat GT1a pts (about 55 percent) versus Harvoni (about 80 percent). “Normalizing for GT1a, where Merck efficacy is inferior (92% vs 96-98% for Harvoni), comparable SVR12s are 95% for Merck vs 96-99% for Harvoni,” the analysts wrote.

The final key dataset for Merck’s HCV doublet, which was presented at EASL, included treatment naïve cirrhotic (22 percent) and non-cirrhotic (78 percent) patients spread between GT1a (50 percent), GT1b (42 percent), GT4 (6 percent) and GT6 (3 percent). SVR12 was 92% in GT1a, 99 percent in GT1b, 100 percent in GT4 and 80 percent in GT6.

In the report Morgan Stanley noted, “Skews in the harder to treat and more prevalent GT1a patients distort headline SVR12; Harvoni clearly remains best in class…while Gilead had between 67-80% of patients in its PhIII ION-1/3 studies with GT1a, only 55% of patients in Merck’s study had GT1a.”

“Given that GT1a represents ~70% of the US market, physicians are very focused on GT1a efficacy. Thus, the poor showing from Merck in GT1a (92% SVR12 vs 96-98% for Harvoni) is a clear weakness given our prior physician feedback that 95% SVR12 is their bar for clinical use,” the analysts explained.

“Other key…
continue reading

Hero Discounts: A Negative GoPro Signal?

Courtesy of Benzinga.

Hero Discounts: A Negative GoPro Signal?

Related GPRO
Pachter: There's Only One GoPro
Cleveland Research: GoPro Undervalued In Near-Term By 20%
Juniper's IPO Base Overcame Volatility (Investor’s Business Daily)

In a report published Friday, analysts at Pacific Crest Securities reiterated their Sector Weight rating on GoPro Inc (NASDAQ: GPRO). The analysts expect the company to post a "beat and raise" quarters going forward, versus the estimates, driven by incremental international distribution.

Increasing international distribution is expected to be the largest contributor to upside in the forthcoming quarters. "While we anticipate strong quarterly results, we will be looking for signs of whether discounting is isolated or more systematic, which would fuel the bear case of commodization," the analysts said.

Related Link: Pachter: There's Only One GoPro

Best Buy Co Inc (NYSE: BBY) is running a 7.5 percent in-store discount offer on Hero 4 Silver till May 2, although the analysts are unsure why Best Buy has not been advertising the offer to pull in more store traffic. While this one-off discounting is unlikely to have any material impact, further evidence of such discounting could fuel the case for bear's commoditization.

According to Pacific Crest, "We continue to believe the company left itself room to the upside in the March quarter in the event of solid sell-through. Given our checks through the quarter, we are comfortable with our above-consensus estimates."

The analysts believe that GoPro continues to hold a dominant market position.

Latest Ratings for GPRO

Date Firm Action From To
Apr 2015 Piper Jaffray Upgrades Neutral Overweight
Mar 2015 Dougherty & Company Upgrades Neutral Buy
Mar 2015 Baird Upgrades Neutral Outperform

View More Analyst Ratings for GPRO
View the Latest Analyst Ratings

Posted-In: Pacific Crest SecuritiesAnalyst Color Reiteration Analyst Ratings Tech Best of Benzinga

Stocks Hitting 52-Week Highs

Courtesy of Benzinga.

Related JNPR
Morning Market Gainers
Benzinga's Top Upgrades
Premarket Gainers / Losers as of 9:15 am (Seeking Alpha)

7 Trends Drug Investors Should Know
Benzinga's Top Initiations
IMS Health beats by $0.07, beats on revenue (Seeking Alpha)

Juniper Networks, Inc. (NYSE: JNPR) shares climbed 9.17 percent to touch a new 52-week high of $26.20 after the company reported better-than-expected results for the first quarter.

IMS Health Holdings Inc (NYSE: IMS) shares reached a new 52-week high of $29.17 after the company reported stronger-than-expected earnings for the first quarter.

Starbucks Corporation (NASDAQ: SBUX) shares climbed 5.08 percent to reach a new 52-week high of $51.94. Starbucks reported in-line earnings for the second quarter. However, the company’s sales exceeded analysts’ estimates.

Cynosure, Inc. (NASDAQ: CYNO) shares touched a new 52-week high of $33.665. Cynosure shares have jumped 33.56 percent over the past 52 weeks, while the S&P 500 index has gained 13.39 percent in the same period.

Posted-In: 52-Week HighsNews Intraday Update Markets Movers

Benzinga's Top Initiations

Courtesy of Benzinga.

Benzinga's Top Initiations

Related QURE
Chardan Capital Initiates UniQure At Buy
Benzinga's Volume Movers

Related DARA
H.C. Wainwright Initiates DARA Biosciences With Buy
DARA Biosciences Reports Waiver of Product Granted, Fees by FDA Established

Analysts at Chardan Capital initiated coverage on UniQure NV (NASDAQ: QURE) with a Buy rating. The target price for UniQure is set to $40. UniQure shares closed at $26.37 yesterday.

Analysts at H.C. Wainwright initiated coverage on DARA Biosciences Inc (NASDAQ: DARA) with a Buy rating. The target price for DARA Biosciences is set to $2. DARA Biosciences’ shares closed at $0.770 yesterday.

Analysts at Nomura initiated coverage on Coca-Cola Femsa, S.A.B. de C.V. (ADR) (NYSE: KOF) with a Neutral rating. The target price for Coca-Cola Femsa is set to $82. Coca-Cola Femsa shares closed at $78.68 yesterday.

Maxim Group initiated coverage on Radius Health Inc (NASDAQ: RDUS) with a Buy rating. The target price for Radius Health is set to $50. Radius Health shares closed at $41.96 yesterday.

Analysts at Roth Capital initiated coverage on Juniper Pharmaceuticals Inc (NASDAQ: JNP) with a Buy rating. The target price for Juniper Pharmaceuticals is set to $15. Juniper Pharmaceuticals’ shares closed at $7.48 yesterday.

Bank of America initiated coverage on Boulder Brands Inc (NASDAQ: BDBD) with a Neutral rating. The target price for Boulder Brands is set to $10.50. Boulder Brands’ shares closed at $10.19 yesterday.

Analysts at UBS initiated coverage on Encana Corporation (USA) (NYSE: ECA) with a Buy rating. Encana’s shares closed at $14.12 yesterday.

UBS initiated coverage on Canadian Natural Ltd (USA) (NYSE: CNQ) with a Buy rating. Canadian Natural shares closed at $33.63 yesterday.

Latest Ratings for QURE

Date Firm Action From To
Apr 2015 Chardan Capital Initiates Coverage on Buy
Apr 2015 BMO Capital Initiates Coverage on Outperform
Apr 2015 Jefferies Maintains Buy

View More Analyst Ratings for QURE
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

Cowen & Co Analyzes Dr. Pepper Snapple's Earnings

Courtesy of Benzinga.

Related DPS
Earnings Scheduled For April 23, 2015
Are Consumers Being Deceived About Organic Foods?
Dr Pepper Snapple Group (Investor’s Business Daily)

In a report published Friday, Cowen & Co analysts maintained a Market Perform rating on Dr Pepper Snapple Group Inc. (NYSE: DPS), with a price target of $80, after the company reported its 1Q15 results,

Dr Pepper Snapple Group reported its core EPS at $0.81, representing 10.2 percent growth. The figure was better than Cowen’s estimate of $0.78 and the consensus of $0.76.

Net sales growth came in at 3.8 percent, with local currency net sales growth at 4.8 percent, being unfavorably impacted by 1 percent due to currency headwinds. Volumes contributed 2 percent to sales growth, with a healthy price/mix of 2.8 percent accounting for the balance. Pro forma operating income grew 9.3 percent.

“The strong quarter was driven by growth across all three of the company’s operating segments,” the analysts said.

In the report Cowen & Co noted, “The beverage concentrates segment grew local currency net sales by 2.4%, driven by a robust 4.4% of price/mix as volumes declined 2.0%…The packaged beverage segment performed well, with net sales (reported and local currency) increasing by 4.7%. The increase was driven by impressive volume growth of 4% and favorable product mix, partially offset by higher promotional spending.”

The company maintained its previous guidance for FY15 EPS at $3.80-$3.88.

Latest Ratings for DPS

Date Firm Action From To
Apr 2015 Susquehanna Initiates Coverage on Neutral
Mar 2015 Stifel Nicolaus Upgrades Hold Buy
Feb 2015 Citigroup Maintains Neutral

View More Analyst Ratings for DPS
View the Latest Analyst Ratings

Posted-In: Cowen & CoAnalyst Color Reiteration Analyst Ratings

FBR Capital Downgrades Capital One Financial To Market Perform

Courtesy of Benzinga.

Related COF
Capital One Financial Q1 Earnings Top Views
Earnings Scheduled For April 23, 2015
Capital One Financial (COF) Richard D. Fairbank on Q1 2015 Results – Earnings Call Transcript (Seeking Alpha)

FBR Capital downgraded Capital One Financial Corp. (NYSE: COF) from Outperform to Market Perform.

The price target for Capital One Financial has been lowered from $94.00 to $87.00.

Capital One Financial shares have gained 11.62 percent over the past 52 weeks, while the S&P 500 index has surged 13.39 percent in the same period.

Capital One Financial shares rose 0.48 percent to $82.25 in after-hours trading.

Latest Ratings for COF

Date Firm Action From To
Apr 2015 FBR Capital Downgrades Outperform Market Perform
Apr 2015 FBR Capital Downgrades Outperform Market Perform
Mar 2015 Oppenheimer Maintains Outperform

View More Analyst Ratings for COF
View the Latest Analyst Ratings

Posted-In: FBR CapitalDowngrades Analyst Ratings

RBC Capital Upgrades Juniper Networks To Outperform

Courtesy of Benzinga.

Related JNPR
Benzinga's Top #PreMarket Gainers
Credit Suisse Reviews Juniper's Earnings
The Vetr community has upgraded $JNPR to 3.5-Stars. (Vetr)

RBC Capital upgraded Juniper Networks, Inc. (NYSE: JNPR) from Sector Perform to Outperform.

The price target for Juniper Networks has been raised from $22.00 to $29.00.

Juniper Networks shares have dropped 1.96 percent over the past 52 weeks, while the S&P 500 index has surged 13.39 percent in the same period.

Juniper Networks’ shares climbed 6.75 percent to $25.62 in pre-market trading.

Latest Ratings for JNPR

Date Firm Action From To
Apr 2015 RBC Capital Upgrades Sector Perform Outperform
Mar 2015 Goldman Sachs Upgrades Neutral Buy
Jan 2015 Deutsche Bank Maintains Hold

View More Analyst Ratings for JNPR
View the Latest Analyst Ratings

Posted-In: RBC CapitalUpgrades Analyst Ratings

The Soda Industry Is Undergoing 'Big Changes'

Courtesy of Benzinga.

The Soda Industry Is Undergoing 'Big Changes'
Related KO
Analyst Sees Turnaround Pressure Building At Coca-Cola
Cramer: Coca-Cola Is The Conservative Way To Play 2 Huge Trends
High-Yield Placeholders For Dividend Champions (Seeking Alpha)
Related PEP
Credit Suisse On Pepsi Earnings: Organic Growth Benefits From Pricing
US Stock Futures Down Ahead Of Earnings, Economic Data
PepsiCo rethinks sweeteners (Seeking Alpha)

In a new report, Citi Research explained its key takeaways from the 2015 Beverage Forum Conference in Chicago.

According to the firm's analysts, The Coca-Cola Co (NYSE: KO) has positioned itself well for the short-term, but they believe the long-term industry-wide changes in the non-alcoholic beverage business could pose a challenge for the company.

Beverage Trends

Product innovation was a key topic of discussion at the conference. In the alcoholic beverage space, innovation in craft beer, flavored bourbon and flavored malt beverages has “materially depressed” sales of more traditional lagers and spirits.

Analysts believe that innovation will be a key to success in the non-alcoholic beverage space as well in upcoming years.

While Coca-Cola and Pepsico, Inc. (NYSE: PEP) have made strides to expand product offerings in recent years, analysts see increasing demand for “specialized” beverages.

Related Link: Why Susquehanna Thinks Sodastream Is Worth $24/Share

Thirsty Millennials

The fastest-growing beverage demographic is millennials, and beverage companies are scrambling to keep up with the group's unique taste. Analysts explain that millennials prefer healthier beverages, customized flavors and packaging and a constant stream of new product offerings.

Coke Executive Speaks

Analysts attended a talk by Senior Vice President of Coca-Cola’s Sparkling Brands Katie Bayne. Bayne explained that the majority of Coca-Cola’s marketing efforts in 2015 will be focused on the core Coke brand.

Bayne added that Monster Beverage Corp (NASDAQ: MNST) and Keurig Green Mountain Inc (NASDAQ: GMCR) provide “different formats which offer a different pacing of caffeine,” allowing at-home consumers more…
continue reading

DA Davidson Upgrades Rudolph Technologies To Buy

Courtesy of Benzinga.

Related RTEC
D.A. Davidson Raises Price Target On Rudolph Technologies As Hybrid Model Drives Strong Beat & Raise Quarter
Earnings Scheduled For February 2, 2015
ASML, ASMI, ACLS, RTEC rally following LRCX's results/guidance (Seeking Alpha)

DA Davidson upgraded Rudolph Technologies Inc (NYSE: RTEC) from Neutral to Buy.

The price target for Rudolph Technologies has been raised from $13.00 to $15.00.

Rudolph Technologies shares have gained 5.05 percent over the past 52 weeks, while the S&P 500 index has surged 12.21 percent in the same period.

Rudolph Technologies’ shares rose 1.97 percent to $11.89 in pre-market trading.

Latest Ratings for RTEC

Date Firm Action From To
Apr 2015 DA Davidson Upgrades Neutral Buy
Mar 2015 DA Davidson Downgrades Buy Neutral
Jan 2015 Barrington Research Upgrades Market Perform Outperform

View More Analyst Ratings for RTEC
View the Latest Analyst Ratings

Posted-In: DA DavidsonUpgrades Analyst Ratings


Zero Hedge

The Next Round of the Great Crisis is at Our Doorstep

Courtesy of ZeroHedge. View original post here.

Submitted by Phoenix Capital Research.

The next round of the financial crisis is at our doorstep.

Central Bankers bet the financial system that their academic theories would work, despite the countless real-world examples showing that printing money does not generate growth.

After all… we know that…

1)   Stocks are expensive by just about every conceivable metric.

2)   Global GDP growth is overstated dramatically with China at most growing 3.5% per year, the US in recession, and Europe in a full-scale DE-pression.

3)   QE is completely useless at generating growth with Japan in a triple dip recession after launching a QE program equal to 25% of its GDP and the US in...

more from Tyler

Phil's Favorites

News You Can Use, 4-25-15 P.M.

The "War On Cash" Migrates To Switzerland (Acting-Man)

Banks Increasingly Refuse Cash Withdrawals – Switzerland Joins the Fun

The war on cash is proliferating globally. It appears that the private members of the world’s banking cartels are increasingly joining the fun, even if it means trampling on the rights of their customers.

Yesterday we came across an article at Zerohedge, in which Dr. Salerno of the Mises Institute notes that JP Morgan Chase has apparently joined the “war on cash”, by “restricting the use of cash in selected markets, restricting borrowers from making cash payments on credit cards, mortgages, equity lines and auto loans, as well as prohibiting storage of cash in safe deposit boxes&rdqu...

more from Ilene

Chart School

World Markets Weekend Update: The Rally Resumes

Courtesy of Doug Short.

Seven of the eight indexes on our world watch list traded higher this week, with China's Shanghai Composite as the top performer, up 2.48%. India's SENSEX was the outlier to the south, with a -3.53% contraction. In fact, the average of the seven gainers was an impressive 1.52%. But the SENSEX pulls the overall average down to 0.89%.

The Shanghai Composite looks to be in bubble mode, up 92% from its interim trough in late October.

Here is an overlay of the eight for a sense of their comparative performance so far in 2015.

Here is a table of the 2015 data performance, sorted from high to low, along with the interim highs for the eight indexes. All eight indexes are in the green, with the top five gains ranging 14.72% to 35.83%. Not bad for a mid-April checkpoint.

A Closer Look at t...

more from Chart School

All About Trends

Mid-Day Update

Reminder: David is available to chat with Members, comments are found below each post.

Click here for the full report.

To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Kimble Charting Solutions

King Dollar slipping below support, say Joe Friday

Courtesy of Chris Kimble.


King Dollar has been on a role since last summer, up over 20% in less than a year. When looking back on the US$, the rally has been rare and nearly historic. Majority of the rally took place inside the steep rising channel above. Over the past month the US$ might have put in a double top. Over the past few days, the US$ has slipped a little below rising support at red arrow above.


As you can see from the table abo...

more from Kimble C.S.

Digital Currencies

Why Bitcoin's male domination will be its downfall

Here's an interesting argument by Felix Salmon, although I think he is taking two correct observations and mistakenly attributing a cause-and-effect relationship to them: Bitcoin is going nowhere because women are not involved.

More likely, in my opinion, women are not involved in bitcoin because bitcoin is going nowhere (and they know it). Or maybe, simply, bitcoin is going nowhere and women are not involved. 

Why Bitcoin's male domination will be its downfall 

By Felix Salmon

Nathaniel Popper’s new book, Digital Gold, is as close as you can get to being the definitive account of the history of Bitcoin. As its subtitle proclaims, the book tells the story of the “misfits” (the first generation of hacker-l...

more from Bitcoin


Swing trading portfolio - week of April 20th, 2015

Reminder: OpTrader is available to chat with Members, comments are found below each post.


This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...

more from OpTrader


Sector Detector: Earnings and GDP temporarily take investor spotlight off the Fed

Reminder: Sabrient is available to chat with Members, comments are found below each post.

Courtesy of Sabrient Systems and Gradient Analytics

As we get into the heart of earnings season and anticipate the GDP report for Q1, the investor spotlight has been taken off the Federal Reserve and timing of its first interest rate hike, at least temporarily. Even though Q1 economic growth will undoubtedly look weak, the future remains bright for the U.S economy – even though many multinationals will struggle with top-line growth due to the strong dollar – and any near-term selloff resulting from weak economic or earnings news should be bought yet again in expectation of better results for the balance of the year. High sector correlations remain a concern, reflectin...

more from Sabrient


Watch the Phil Davis Special on Money Talk on BNN TV!

Kim Parlee interviews Phil on Money Talk. Be sure to watch the replays if you missed the show live on Wednesday night (it was recorded on Monday). As usual, Phil provides an excellent program packed with macro analysis, important lessons and trading ideas. ~ Ilene


The replay is now available on BNN's website. For the three part series, click on the links below. 

Part 1 is here (discussing the macro outlook for the markets) Part 2 is here. (discussing our main trading strategies) Part 3 is here. (reviewing our pick of th...

more from Promotions

Market Shadows

Kimble Charts: South Korea's EWY

Kimble Charts: South Korea's EWY

By Ilene 

Chris Kimble likes the iShares MSCI South Korea Capped (EWY), but only if it breaks out of a pennant pattern. This South Korean equities ETF has underperformed the S&P 500 by 60% since 2011.

You're probably familiar with its largest holding, Samsung Electronics Co Ltd, and at least several other represented companies such as Hyundai Motor Co and Kia Motors Corp.


more from Paul

Mapping The Market

S&P 500 Leverage and Hedges Options - Part 2

Courtesy of Jean-Luc Saillard.

In my last post (Part 1 of this article), I looked at alternative ETFs that could be used as hedges against the corrections that we have seen during that long 2 year bull run. Looking at the results, it seems that for short (less than a month) corrections, a VIX ETF like VXX could actually be a viable candidate to hedge or speculate on the way down. Another alternative ETF was TMF, a long Treasuries ETF which banks on the fact that when markets go down, money tends to pack into treasuries viewed as safe instruments. In some cases, TMF even outperformed the usual hedging instruments like leveraged ETFs. There could of course be other factors at play since some of 2014 corrections were related to geopolitical events which are certain...

more from M.T.M.


2015 - Biotech Fever

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

PSW Members - well, what a year for biotechs!   The Biotech Index (IBB) is up a whopping 40%, beating the S&P hands down!  The healthcare sector has had a number of high flying IPOs, and beat the Tech Sector in total nubmer of IPOs in the past 12 months.  What could go wrong?

Phil has given his Secret Santa Inflation Hedges for 2015, and since I have been trying to keep my head above water between work, PSW, and baseball with my is time that something is put together for PSW on biotechs in 2015.

Cancer and fibrosis remain two of the hottest areas for VC backed biotechs to invest their monies.  A number of companies have gone IPO which have drugs/technologies that fight cancer, includin...

more from Pharmboy

Help One Of Our Own PSW Members

"Hello PSW Members –

This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at with any questions.

Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

Thank you for you time!

FeedTheBull - Top Stock market and Finance Sites

About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>

As Seen On:

About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>